Información del artículo
Tenofovir (TDF) es uno de los fármacos de elección en las combinaciones de tratamiento antirretroviral de primera línea. La mayor parte de la información acerca de su eficacia y seguridad en este escenario se originó inicialmente en ensayos clínicos en los que se combinaba con no análogos de nucleósidos. Este hecho, así como la posible interacción de TDF con algunos inhibidores de proteasa (IP) y la sospecha de que esta combinación pudiera incrementar el riesgo de nefrotoxicidad, hace imprescindible analizar la experiencia clínica disponible de la combinación de TDF (asociado a emtricitabina u otro análogo de nucleósido) con un IP. En esta revisión se presentan los datos de eficacia y seguridad procedentes en su mayoría de ensayos clínicos. Tomados en su conjunto, estos estudios aportan suficiente información para poder afirmar que la combinación de TDF con IP es eficaz y segura, lo que justifica su elección en el tratamiento de primera línea o en el rescate tras el fracaso virológico.
Palabras clave:
Tenofovir
Inhibidor de proteasa
Eficacia
Seguridad
Tenofovir is one of the drugs of choice in first-line combinations of antiretroviral therapy. Most data on safety and efficacy in this scenario initially came from clinical trials in which tenofovir was combined with non-nucleoside reverse transcriptase inhibitors. Because of this, as well as the possible interaction of tenofovir with some protease inhibitors and the suspicion that this combination could increase the risk of nephrotoxicity, analysis of the clinical experience available on the combination of tenofovir (associated with emtricitabine or another nucleoside analogue) with a protease inhibitor is essential. The present review reports data on efficacy and safety, mainly from clinical trials. Taken together, these studies provide sufficient information to indicate that the combination of tenofovir and protease inhibitors is safe and effective, justifying its selection in first-line therapy or rescue therapy after virological failure.
Key words:
Tenofovir
Protease inhibitor
Efficacy
Safety
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.S. Mulato, J.M. Cherrington.
Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
Antiviral Res, 36 (1997), pp. 91-97
[2.]
C. Ying, E. De Clercq, J. Neyts.
Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture.
J Viral Hepat, 7 (2000), pp. 79-83
[3.]
M. Boffito, D. Back, M. Stainsby-Tron, A. Hill, G. Di Perri, G. Moyle, et al.
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Br J Clin Pharmacol, 59 (2005), pp. 38-42
[4.]
M. Kurowski, R.K. Walli, A. Breske, G. Kruse, H. Stocker, N. Banik, et al.
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
Aids, 21 (2007), pp. 1368-1370
[5.]
D.A. Parks, H.C. Jennings, C.W. Taylor, E.P. Acosta.
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
Aids, 21 (2007), pp. 1373-1375
[6.]
B.P. Kearney, A. Mittan, J. Sayre, R. Ebrahimi, A.K. Cheng.
Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir.
J Acquir Immune Defic Syndr, 43 (2006), pp. 278-283
[7.]
R.M. Hoetelmans, K. Marien, M. De Pauw, A. Hill, M. Peeters, V. Sekar, et al.
Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.
Br J Clin Pharmacol, 64 (2007), pp. 655-661
[8.]
E. Dailly, O. Tribut, P. Tattevin, C. Arvieux, P. Perre, F. Raffi, et al.
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Eur J Clin Pharmacol, 62 (2006), pp. 523-526
[9.]
A.M. Taburet, C. Piketty, C. Chazallon, I. Vincent, L. Gerard, V. Calvez, et al.
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother, 48 (2004), pp. 2091-2096
[10.]
L.P.T. Tong, K.L. Robinson, D. Babusis, et al.
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Antimicrob Agents Chemother, 51 (2007), pp. 3498-3504
[11.]
J.J. Kiser, M.L. Carten, C.L. Aquilante, P.L. Anderson, P. Wolfe, T.M. King, et al.
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Clin Pharmacol Ther, 83 (2008), pp. 265-272
[12.]
T. Cihlar, A.S. Ray, G. Laflamme, J.E. Vela, L. Tong, M.D. Fuller, et al.
Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
Antivir Ther, 12 (2007), pp. 267-272
[13.]
B.L. Robbins, R.V. Srinivas, C. Kim, N. Bischofberger, A. Fridland.
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.
Antimicrob Agents Chemother, 42 (1998), pp. 612-617
[14.]
D. Gilden.
Tenofovir: Gilead applies for approval; expanded access liberalized.
AIDS Treat News, 364 (2001),
[15.]
P.R. Harrigan, M.D. Miller, P. McKenna, Z.L. Brumme, B.A. Larder.
Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.
Antimicrob Agents Chemother, 46 (2002), pp. 1067-1072
[16.]
J.E. Gallant, A.L. Pozniak, E. DeJesús, S. Staszewski, J. Soleiman, M.D. Miller, et al.
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial.
JAMA, 292 (2004), pp. 191-201
[17.]
J.E. Gallant, J.R. Arribas, A.L. Pozniak, E. DeJesus, B. Gazzard, R.E. Campo, et al.
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
N Engl J Med, 354 (2006), pp. 251-260
[18.]
H.R. Crane, S. Van Rompaey, M. Kitahata.
Didanosine and lower baseline body weight are associated with declining renal function among patients receiving tenofovir.
13th Conference on Retroviruses and Opportunistic Infections,
[19.]
M. Johnson, B. Grinsztejn, C. Rodriguez, J. Coco, E. DeJesús, A. Lazzarin, et al.
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
AIDS, 20 (2006), pp. 711-718
[20.]
M.A. Johnson, J.C. Gathe, D. Podzamczer, J.M. Molina, C.T. Naylor, Y.L. Chiu, et al.
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.
J Acquir Immune Defic Syndr, 43 (2006), pp. 153-160
[21.]
J. Gathe, B. da Silva, M. Loutfy, D. Podzamczer, R. Rubio, S. Gibbs, et al.
Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir (LPV/r) tablets once daily (QD) versus twice daily (BID), co-administratered with tenofovir DT (TDF) + emtricitabine (FTC) in antiretroviral-naïve (ARN) HIV-1 infected subjects.
15th Conference on Retrovirus and Opportunistic Infection,
[22.]
J.M. Molina, J. Andrade-Villanueva, J. Echevarría, P. Chetchotisakd, J. Corral, N. David, et al.
Efficacy and safety of one-daily atazanavir/ritonavir compared to twice- daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabinein ARV-naïve HIV- 1 infected subjets: The CASTLE Study, 48-week Results.
15th Conference on Retrovirus and Opportunistic Infection,
[23.]
S. Walmsley, K. Ruxrungtham, J. Slim, D. Ward, P. Larson, F. Raffi.
Saquinavir/r (SQV/r) BiD versus lopinavir/r (LPV/r) BiD, plus emtricitabine/tenofovir (FTC/TDF) QD as initial therapy in HIV-1 infected patients: the GEMINI study.
11th European AIDS Conference, Madrid,
[24.]
E. DeJesús, R. Ortiz, H. Khanlou, E. Voronin, J. Van Lunzen, J. Andrade-Villanueva, et al.
Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naïve HIV-1 infected patients at week 48: ARTEMIS (TMC114-C 211).
Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
[25.]
K. Smith, D. Fine, P. Patel, N. Bellos, L. Sloan, P. Lackey, et al.
Efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with once daily lopinavir /ritonavir through 48 weeks in the HEAT Study.
15th Conference on Retrovirus and Opportunistic Infection,
[26.]
A. Collado, J.A. Pineda, E. Condes, I. Ocaña, F. Pasquau, M. Cervero, et al.
Effectiveness and safety of HAART regimens containing tenofovir DF + protease inhibitors in HIV/HVC co-Infected vs non-coinfected patients. Subanalysis from the Protection Spanish Cohort.
3rd Intenational Workshop on HIV and Hepatitis Coinfection,
[27.]
J.M. Llibre, M.J. Galindo, M. Márquez, J. Berenguer, S. Echevarría, L.E. Morano, et al.
Evolution of the lipid profile changes in patients treated with tenofovir DF and protease inhibitors. Data from the PROTECTION Cohort Study.
9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Sydney, Australia,
[28.]
P. Viciana, E. Deig, V. Asensi, J. Pasquau, T. Martín, J. Goiloetxea, et al.
Renal safety profile of TDF in combination with protease inhibitors (PI) in a clinical setting. Results from the PROTECTION Cohort.
9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV,
[29.]
M. Márquez, J. Pasquau, J.A. Pineda, A. López Burgos, J. Hernández Burrezo, M.L. Álvarez, et al.
Efectividad y seguridad de tenofovir DF y abacavir en combinación con inhibidores de la proteasa. Resultados de la cohorte PROTECTION.
X Congreso de la Sociedad Andaluza de Enfermedades Infecciosas,
[30.]
M. Goicoechea, S. Liu, B. Best, S. Sun, S. Jain, C. Kemper, et al.
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
J Infect Dis, 197 (2008), pp. 102-108
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
